Short Interest in Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) Increases By 63.1%

Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) saw a large increase in short interest during the month of May. As of May 29th, there was short interest totaling 123,876 shares, an increase of 63.1% from the May 14th total of 75,959 shares. Based on an average trading volume of 738,378 shares, the days-to-cover ratio is presently 0.2 days. Currently, 10.2% of the company’s shares are short sold.

Aspire Biopharma Price Performance

NASDAQ ASBP opened at $6.19 on Wednesday. Aspire Biopharma has a 12 month low of $3.31 and a 12 month high of $1,050.36. The company has a 50-day moving average of $10.05 and a 200-day moving average of $50.31. The company has a market cap of $8.05 million, a P/E ratio of -0.05 and a beta of 0.17.

Aspire Biopharma (NASDAQ:ASBP) last posted its quarterly earnings data on Friday, May 15th. The company reported ($20.57) EPS for the quarter. The firm had revenue of $0.03 million for the quarter.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aspire Biopharma in a research note on Monday, April 20th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of ASBP. CIBC Bancorp USA Inc. purchased a new stake in shares of Aspire Biopharma during the 3rd quarter worth about $28,000. XTX Topco Ltd grew its holdings in shares of Aspire Biopharma by 853.2% during the 4th quarter. XTX Topco Ltd now owns 265,471 shares of the company’s stock worth $35,000 after purchasing an additional 237,620 shares during the period. Finally, Jane Street Group LLC grew its holdings in shares of Aspire Biopharma by 625.8% during the 2nd quarter. Jane Street Group LLC now owns 152,552 shares of the company’s stock worth $41,000 after purchasing an additional 131,533 shares during the period. Institutional investors and hedge funds own 19.17% of the company’s stock.

About Aspire Biopharma

Aspire Biopharma Inc is a specialty pharmaceutical company dedicated to developing and commercializing inhaled therapeutics for cardiopulmonary emergencies and respiratory diseases. The firm leverages proprietary formulation and drug-delivery technologies to repurpose established active pharmaceutical ingredients, aiming to enhance onset of action and improve patient convenience in acute settings. Aspire’s focus on pulmonary administration differentiates its approach from traditional oral or injectable treatments for asthma, allergic reactions, and other respiratory conditions.

The company’s lead asset is a reformulated metered-dose inhaler version of epinephrine designed to serve as an over-the-counter or prescription rescue therapy for acute bronchospasm and anaphylaxis.